Fiche centre
University of Washington
Seattle — United States
Essais liés23clinical trials
VilleSeattlelocalisation
PaysUnited Stateslocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT07164443
Essais cliniques associés
23| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Percutaneous Mechanical Circulatory Support | Maladie coronarienne | Non applicable | NCT06445608 | PIvotal Trial of the KARDION Cory P4 MechANical Circulatory SupporT SystEm | RECRUITING |
| Non-invasive Electrical Spinal Cord Stimulation | Accident vasculaire cérébral | Non applicable | NCT05591196 | HARNESS — Hand and Arm Motor Recovery Via Non-invasive Electrical Spinal Cord Stimulation After Stroke | RECRUITING |
| BIA 28-6156 10 mg | Parkinson | Phase 2 | NCT05819359 | ACTIVATE — Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PD | COMPLETED |
| InnAVasc Arteriovenous Graft (IG) surgical implant | Maladie rénale chronique | Non applicable | NCT04671771 | A Study to Evaluate the Safety and Effectiveness of the InnAVasc Arteriovenous Graft for Hemodialysis Access in Patients With End-Stage Renal Disease | RECRUITING |
| Pasritamig | Cancer | Phase 3 | NCT07164443 | KLK2-comPAS — A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC) | RECRUITING |
| Electrical Impedance Myography | Myopathies | À vérifier | NCT03458832 | ReSolve — Clinical Trial Readiness to Solve Barriers to Drug Development in FSHD | ACTIVE_NOT_RECRUITING |
| AOC 1001 (del-desiran) | Myopathies | Phase 3 | NCT06411288 | HARBOR — Global Study of Del-desiran for the Treatment of DM1 | COMPLETED |
| High intensity focused ultrasound, HIFU | Cancer | Phase 1/2 | NCT00637364 | HIFU Pancreas — High Intensity Focused Ultrasound Tumor Treatment for Pancreatic Cancer Pain | SUSPENDED |
| Intravenously administered pooled human immunoglobulin (IVIG) | Myopathies | Phase 2 | NCT06599697 | The MIGHT Trial - An Exploratory Clinical Trial of IVIG in Anti-HMGCR Immune Mediated Necrotizing Myopathy | RECRUITING |
| AOC 1020 | Myopathies | Phase 2 | NCT06547216 | FORTITUDE-OLE — Phase 2 Open-label Extension Study of AOC 1020 in Participants With Facioscapulohumeral Muscular Dystrophy (FSHD) | ACTIVE_NOT_RECRUITING |
| AOC 1020 | Myopathies | Phase 1/2 | NCT05747924 | FORTITUDE — Phase 1/2 Study of AOC 1020 in Participants With Facioscapulohumeral Muscular Dystrophy (FSHD) | COMPLETED |
| 3T Magnetic Resonance Imaging (MRI) | Épilepsie | À vérifier | NCT05823766 | Transforming Research and Clinical Knowledge in Traumatic Brain Injury Epileptogenesis Project (TRACK-TBI EPI) | ACTIVE_NOT_RECRUITING |
| TREAT-MS — Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial | SEP | Non applicable | NCT03500328 | TREAT-MS — Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial | ACTIVE_NOT_RECRUITING |
| ASSESS ALL ALS Study | Sclérose latérale amyotrophique | À vérifier | NCT06578195 | ASSESS ALL ALS Study | RECRUITING |
| ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD) | Sclérose latérale amyotrophique | À vérifier | NCT04363684 | ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD) | RECRUITING |
| PREVENT ALL ALS Study | Sclérose latérale amyotrophique | À vérifier | NCT06581861 | PREVENT ALL ALS Study | RECRUITING |
| Pridopidine | Sclérose latérale amyotrophique | Phase 3 | NCT07322003 | PREVAiLS — Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS | RECRUITING |
| Del-desiran (AOC 1001) | Myopathies | Phase 3 | NCT07008469 | HARBOR-OLE — Global Open-Label Extension Study of Del-desiran for the Treatment of DM1 | ENROLLING_BY_INVITATION |
| extended release metformin | Alzheimer | Phase 2/3 | NCT04098666 | MAP — Metformin in Alzheimer's Dementia Prevention | ACTIVE_NOT_RECRUITING |
| BIA 28-6156 | Parkinson | À vérifier | NCT07522606 | Compassionate Use for BIA 28-6156 in Patients With Parkinson's Disease (PD) Who Have a Pathogenic Variant in the GBA1 Gene (GBA-PD) and Completed the ACTIVATE Study | NO_LONGER_AVAILABLE |
| Memantine | Sclérose latérale amyotrophique | Phase 2 | NCT02118727 | Therapy in Amyotrophic Lateral Sclerosis (TAME) | COMPLETED |
| Mexiletine | Sclérose latérale amyotrophique | Phase 2 | NCT02781454 | Mexiletine in Sporadic Amyotrophic Lateral Sclerosis | COMPLETED |
| Zilucoplan | Sclérose latérale amyotrophique | Phase 2/3 | NCT04297683 | HEALEY ALS Platform Trial - Master Protocol | ACTIVE_NOT_RECRUITING |